Mutational heterogeneity in spike glycoproteins of severe acute respiratory syndrome coronavirus 2.
COVID-19
Glycoproteins
Mutational heterogeneity
SARS-CoV-2
Spike proteins
Journal
3 Biotech
ISSN: 2190-572X
Titre abrégé: 3 Biotech
Pays: Germany
ID NLM: 101565857
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
08
10
2020
accepted:
12
04
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
ppublish
Résumé
The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has led to a global crisis by infecting millions of people across the globe eventually causing multiple deaths. The prominent player of the virus has been known as the spike protein which enters the host system and leads to the infection. The S2 subunit is the most essential in this process of infection as it helps the SARS-CoV-2 to infect the host by binding to the human angiotensin converting enzyme 2 (hACE2), with the help of the receptor binding domain found at the S2 subunit of the virus. Studies also hypothesize that the S glycoproteins present in the virus interacts with different hosts in different ways which might be due to the mutations taking place in the genome of the virus over time. This work aims to decipher the similarities and differences in the sequences of spike proteins from samples of SARS-CoV-2 acquired from different infected individuals in different countries with the help of in silico methods such as multiple sequence alignment and phylogenetic analysis. It also aims to understand the differential infection rates among the infected countries by studying the amino acid composition and interactions of the virus with the host.
Identifiants
pubmed: 33936927
doi: 10.1007/s13205-021-02791-y
pii: 2791
pmc: PMC8070983
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
236Informations de copyright
© King Abdulaziz City for Science and Technology 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
Vaccines (Basel). 2020 Jul 28;8(3):
pubmed: 32731461
Cell Res. 2020 Apr;30(4):343-355
pubmed: 32231345
F1000Res. 2020 May 18;9:371
pubmed: 32595958
EXCLI J. 2020 Mar 18;19:410-417
pubmed: 32210742
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9241-9243
pubmed: 32269081
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Heliyon. 2020 Sep;6(9):e04658
pubmed: 32844125
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Viruses. 2012 Apr;4(4):557-80
pubmed: 22590686
Biochem Biophys Res Commun. 2020 Jun 30;527(3):702-708
pubmed: 32410735
Cancers (Basel). 2020 Dec 14;12(12):
pubmed: 33327542
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
PLoS Pathog. 2020 Mar 9;16(3):e1008392
pubmed: 32150576
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nature. 2020 Aug;584(7819):154-156
pubmed: 32438371
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Front Cell Infect Microbiol. 2022 Nov 28;12:966870
pubmed: 36519126
Cytokine Growth Factor Rev. 2020 Jun;53:38-42
pubmed: 32360420
J Biomol Struct Dyn. 2021 Aug;39(13):4878-4892
pubmed: 32583729